Targeting protein prenylation for cancer therapy

  • Berndt N
  • Hamilton A
  • Sebti S
  • 269

    Readers

    Mendeley users who have this article in their library.
  • 240

    Citations

    Citations of this article.

Abstract

Protein farnesylation and geranylgeranylation, together referred to as prenylation, are lipid post-translational modifications that are required for the transforming activity of many oncogenic proteins, including some RAS family members. This observation prompted the development of inhibitors of farnesyltransferase (FT) and geranylgeranyl-transferase 1 (GGT1) as potential anticancer drugs. In this Review, we discuss the mechanisms by which FT and GGT1 inhibitors (FTIs and GGTIs, respectively) affect signal transduction pathways, cell cycle progression, proliferation and cell survival. In contrast to their preclinical efficacy, only a small subset of patients responds to FTIs. Identifying tumours that depend on farnesylation for survival remains a challenge, and strategies to overcome this are discussed. One GGTI has recently entered the clinic, and the safety and efficacy of GGTIs await results from clinical trials.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Norbert Berndt

  • Andrew D. Hamilton

  • Saïd M. Sebti

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free